Have a question about this calculator? Get a detailed answer.
The Drug Abuse Screening Test (DAST-10) is a 10-item self-report screening instrument developed by Dr. Harvey Skinner in 1982 at the Addiction Research Foundation in Toronto, Canada. It was derived from the original 28-item DAST by selecting the items with the highest item-total correlations, yielding a brief yet psychometrically robust tool for identifying individuals with drug use problems. The DAST-10 specifically excludes alcohol (which is assessed separately by instruments like the AUDIT) and focuses on the use of illicit drugs and the non-medical use of prescription medications. Each of the 10 items requires a yes or no response referring to the past 12 months. One item (question 3: 'Are you always able to stop using drugs when you want to?') is reverse-scored, meaning a 'no' response receives 1 point while a 'yes' response receives 0. All other items score 1 for 'yes' and 0 for 'no.' The total score ranges from 0 to 10, with higher scores indicating more severe drug-related problems. The DAST-10 has been validated across diverse clinical populations including primary care patients, psychiatric inpatients, emergency department patients, pregnant women, and criminal justice populations. It demonstrates good internal consistency (Cronbach alpha of 0.86 to 0.94 across studies), excellent sensitivity (89 to 95 percent) and specificity (68 to 88 percent) at a cutoff score of 1 or higher for any drug problem, and strong correlation with more comprehensive diagnostic assessments. The instrument is recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA) as part of the Screening, Brief Intervention, and Referral to Treatment (SBIRT) protocol. It is endorsed by numerous clinical guidelines as an appropriate companion to the AUDIT for comprehensive substance use screening. The DAST-10 takes approximately 1 to 2 minutes to complete and requires no specialized training to administer.
DAST-10 Score = Sum of all 10 items (each scored 0 or 1) Scoring: - Items 1, 2, 4, 5, 6, 7, 8, 9, 10: Yes = 1, No = 0 - Item 3 (reverse-scored): Yes = 0, No = 1 Worked Example: A 29 year old patient responds to the DAST-10: 1. Have you used drugs other than those required for medical reasons? Yes (1) 2. Do you abuse more than one drug at a time? No (0) 3. Are you always able to stop using drugs when you want to? No (1, reverse-scored) 4. Have you had blackouts or flashbacks as a result of drug use? Yes (1) 5. Do you ever feel bad or guilty about your drug use? Yes (1) 6. Does your spouse or parent ever complain about your involvement with drugs? Yes (1) 7. Have you neglected your family because of your use of drugs? No (0) 8. Have you engaged in illegal activities to obtain drugs? No (0) 9. Have you ever experienced withdrawal symptoms when you stopped taking drugs? Yes (1) 10. Have you had medical problems as a result of your drug use? No (0) DAST-10 Score = 1 + 0 + 1 + 1 + 1 + 1 + 0 + 0 + 1 + 0 = 6 Interpretation: A score of 6 falls in the substantial level category (6-8), indicating a significant degree of drug-related problems. The recommended intervention is intensive assessment and possible outpatient or intensive outpatient treatment.
- 1Prepare the Screening Environment: Administer the DAST-10 in a private, confidential setting. Explain to the patient that the questionnaire asks about drug use (not including alcohol) over the past 12 months, that all responses are confidential within the limits of clinical practice and applicable laws, and that honest responses will help determine the most appropriate care. Clarify that 'drug use' includes illicit drugs (marijuana, cocaine, heroin, methamphetamine, hallucinogens, inhalants) and the non-medical use of prescription medications (opioids, benzodiazepines, stimulants, sedatives). Emphasize that the questionnaire does not ask about alcohol or tobacco.
- 2Administer the 10 Yes/No Questions: Present all 10 questions with yes or no response options. The questions assess: (1) non-medical drug use, (2) polysubstance use, (3) ability to stop (reverse-scored), (4) blackouts or flashbacks, (5) guilt about drug use, (6) complaints from significant others, (7) family neglect, (8) illegal activities to obtain drugs, (9) withdrawal symptoms, and (10) medical problems from drug use. The patient may self-administer the questionnaire on paper or electronically, or the clinician may read the questions aloud. Self-administration generally produces more honest responses for sensitive substance use questions.
- 3Score Each Item Correctly: Assign 1 point for each 'yes' response on items 1, 2, 4, 5, 6, 7, 8, 9, and 10. For item 3 ('Are you always able to stop using drugs when you want to?'), assign 1 point for a 'no' response and 0 points for a 'yes' response. This reverse scoring is the most common source of scoring errors. Double-check item 3 before calculating the total. Sum all 10 items for the total DAST-10 score, which ranges from 0 to 10.
- 4Classify the Severity Level: Interpret the total score using the standard four-level classification: 0 indicates no problems reported; 1 to 2 indicates a low level of drug-related problems; 3 to 5 indicates a moderate level; 6 to 8 indicates a substantial level; and 9 to 10 indicates a severe level. Each level has a corresponding recommended action. Note that even a score of 1 indicates some degree of drug use concern and warrants further clinical inquiry. The classification thresholds have been validated against DSM diagnostic criteria for substance use disorders.
- 5Conduct Follow-Up Assessment Based on Score: For scores of 1 to 2, provide brief advice about drug use risks and monitor at follow-up visits. For scores of 3 to 5, conduct a more detailed assessment of drug use patterns, including type of drugs, frequency, route of administration, and functional impact, and consider brief intervention. For scores of 6 to 8, conduct intensive assessment and consider referral to outpatient addiction treatment. For scores of 9 to 10, conduct intensive assessment and refer for specialized addiction treatment, which may include inpatient or residential treatment depending on clinical circumstances.
- 6Determine Specific Substances and Use Patterns: The DAST-10 does not identify which specific drugs are being used. After scoring, conduct a substance-specific inquiry to determine the type of drugs, frequency of use, route of administration, and duration of use. This information is essential for treatment planning because the intervention approach differs significantly based on the substance involved. Opioid use disorder may require medication-assisted treatment with buprenorphine, methadone, or naltrexone. Stimulant use disorder requires behavioral interventions as no FDA-approved medications exist. Benzodiazepine dependence requires carefully supervised medical taper.
- 7Document and Integrate with Comprehensive Care: Record the DAST-10 score in the medical record alongside other substance use screening results (such as AUDIT for alcohol). Integrate findings with the patient's overall health assessment, considering comorbid medical conditions, psychiatric disorders, and social determinants of health. For patients with dual diagnoses (co-occurring substance use and mental health disorders), coordinate care between addiction and mental health services. Schedule follow-up DAST-10 administration at 3 to 6 month intervals for patients scoring 1 or higher to monitor progress and detect changes in drug use patterns.
This patient reports no drug use or drug-related problems over the past 12 months. No intervention is needed. The result is documented and screening will be repeated at the next annual visit or sooner if clinical concerns arise.
This 34 year old patient uses recreational cannabis weekly and occasionally takes a friend's prescription Adderall for work deadlines. The score of 4 indicates moderate drug-related problems. The patient believes they can stop at any time but acknowledges guilt and complaints from their partner. A brief intervention addressing drug use risks and setting reduction goals is recommended, along with follow-up screening in 3 months.
This 26 year old patient endorses all 10 items, indicating severe drug-related problems across all domains. Further assessment reveals daily use of illicitly obtained fentanyl and intermittent methamphetamine use. The patient experiences withdrawal symptoms, has been involved in illegal activity to obtain drugs, and has had multiple emergency department visits for overdose. Immediate referral for medication-assisted treatment with buprenorphine or methadone is initiated, along with naloxone prescribing for overdose prevention and referral to comprehensive addiction treatment services.
SBIRT Programs in Healthcare Settings: The DAST-10 is a core component of Screening, Brief Intervention, and Referral to Treatment (SBIRT) programs implemented in emergency departments, primary care offices, and community health centers across the United States. SAMHSA has funded SBIRT implementation in all 50 states, and the model has been shown to reduce drug use, improve treatment engagement, and decrease emergency department utilization. A typical SBIRT encounter begins with AUDIT and DAST-10 screening, progresses to brief intervention for moderate scores, and includes direct referral to treatment for high scores.
Prenatal Substance Use Screening: Prenatal care providers use the DAST-10 to screen for drug use during pregnancy, which is associated with preterm birth, low birth weight, neonatal abstinence syndrome (for opioids), and developmental delays. The American College of Obstetricians and Gynecologists recommends universal substance use screening at the first prenatal visit using validated tools. The DAST-10 is preferred over urine drug testing alone because it identifies a broader range of drug-related problems and facilitates a therapeutic conversation about behavior change rather than a punitive approach that may deter prenatal care engagement.
Criminal Justice Diversion and Treatment Courts: Drug courts and criminal justice diversion programs use the DAST-10 as part of their intake assessment to determine eligibility for treatment alternatives to incarceration. Research shows that drug court participants who receive treatment based on validated screening results have 8 to 14 percent lower recidivism rates than those processed through traditional criminal justice pathways. The DAST-10 helps triage participants into appropriate treatment intensity levels, from outpatient counseling for low-scoring individuals to residential treatment for those with severe scores.
Occupational Health and Safety-Sensitive Positions: Employers in safety-sensitive industries (aviation, transportation, nuclear energy, healthcare) use the DAST-10 as part of pre-employment and periodic fitness-for-duty assessments. The DAST-10 complements urine drug testing by identifying patterns of problematic drug use that may not be captured by a single-point-in-time biological test. Employee assistance programs (EAPs) use the DAST-10 to assess employees who self-refer or are referred by supervisors for possible substance use concerns, guiding the level of intervention from brief counseling to intensive outpatient treatment.
When administering the DAST-10 to patients currently in medication-assisted
When administering the DAST-10 to patients currently in medication-assisted treatment (MAT) for opioid use disorder, careful instruction is needed to distinguish between prescribed MAT medications (methadone, buprenorphine) and non-prescribed drug use. Patients on MAT who take their medications as prescribed should answer 'no' to question 1 regarding their MAT medication but 'yes' if they are using other non-prescribed substances. Without this clarification, MAT patients may falsely elevate their DAST-10 scores by including their prescribed treatment medication. In jurisdictions where marijuana has been legalized for recreational or medical use, patients may be confused about whether to include cannabis in their DAST-10 responses. The correct approach is to include any drug use that is causing problems, regardless of legal status. Medical marijuana patients should include their use if it is causing any of the problems described in the DAST-10 questions (guilt, blackouts, complaints from others, inability to stop, neglect of responsibilities). Special consideration is needed for patients with chronic pain who may be taking opioid medications as prescribed but experiencing dose escalation, early refill requests, or functional decline. These patients may score positive on the DAST-10 even when their medication use began as appropriately prescribed treatment. The distinction between prescription opioid use disorder and appropriate medical use of opioids requires careful clinical assessment beyond what the DAST-10 can provide.
| Score Range | Severity Level | Suggested Action | Treatment Intensity | Follow-Up |
|---|---|---|---|---|
| 0 | No problems reported | No action required | None | Annual screening |
| 1-2 | Low level | Brief advice and monitoring | Minimal | 6 months |
| 3-5 | Moderate level | Brief intervention | Outpatient counseling | 3 months |
| 6-8 | Substantial level | Intensive assessment | Outpatient or intensive outpatient | 1-3 months |
| 9-10 | Severe level | Intensive assessment and referral | Inpatient or residential | As clinically indicated |
Does the DAST-10 include prescription medications?
Yes, but only the non-medical use of prescription medications. The DAST-10 instructions specify that drug use includes taking prescription medications in excess of the directions or for purposes other than those for which they were prescribed, as well as any non-medical use of drugs. Taking prescribed medications exactly as directed by a physician is not considered drug use for DAST-10 purposes. Patients should be clearly instructed to distinguish between appropriate medical use and non-medical use. Common examples of non-medical prescription drug use include taking higher doses than prescribed, using medications prescribed for someone else, and using prescription opioids or stimulants for their euphoric effects.
Why is alcohol excluded from the DAST-10?
Alcohol is excluded because it is assessed by separate, specialized instruments (primarily the AUDIT) and because including alcohol would confound the drug use assessment. Alcohol use is so prevalent that including it would reduce the DAST-10's ability to discriminate between individuals with and without drug-specific problems. Additionally, the intervention pathways for alcohol use disorders and drug use disorders often differ significantly. Using separate instruments allows clinicians to develop targeted intervention plans for each substance category. In clinical practice, the DAST-10 and AUDIT should be administered together for comprehensive substance use screening.
How does the DAST-10 perform in different populations?
The DAST-10 has been validated across diverse populations with generally strong psychometric performance. In primary care settings, it demonstrates sensitivity of 89 to 95 percent and specificity of 68 to 88 percent. In psychiatric populations, sensitivity remains high but specificity may be lower due to overlapping symptoms. In pregnant women, the DAST-10 has been shown to outperform urine drug testing for identifying drug use problems. In adolescent populations, some studies suggest that the cutoff scores may need adjustment. In criminal justice populations where drug use prevalence is very high, the DAST-10 is more useful for severity classification than for screening per se.
Can the DAST-10 be used for marijuana now that it is legal in many states?
Yes. The DAST-10 assesses drug-related problems regardless of the legal status of the substance. Legal cannabis use can still be associated with significant problems including impaired driving, workplace performance issues, cannabis use disorder, cognitive effects, and respiratory problems from smoking. The legality of a substance does not eliminate the potential for problematic use patterns. Similarly, the DAST-10 captures problems from legally obtained prescription medications used non-medically. When administering the DAST-10 in states where cannabis is legal, clarify that the questionnaire is about problems associated with use, not about legal consequences.
What is the difference between the DAST-10 and the DAST-20?
The DAST-10 was derived from the DAST-20 (which itself was derived from the original DAST-28) by selecting the 10 items with the highest correlation to the full scale. The DAST-10 captures approximately 92 percent of the variance of the DAST-20 while taking half the time to administer. For most clinical screening purposes, the DAST-10 is preferred because it is more practical and nearly as accurate. The DAST-20 may be preferred in research settings where slightly greater precision is desired or in specialized addiction treatment programs where a more detailed initial assessment is warranted.
Should the DAST-10 be administered before or after the AUDIT?
There is no strict requirement for ordering, but most SBIRT protocols administer the AUDIT first followed by the DAST-10. This ordering has a practical advantage: the AUDIT begins with straightforward consumption questions that are less stigmatized, creating a conversational momentum that makes the more sensitive drug use questions feel more natural. Additionally, explicitly separating alcohol (AUDIT) from other drugs (DAST-10) reinforces the instruction that the DAST-10 excludes alcohol. Some electronic health record systems combine both instruments into a single substance use screening workflow.
Pro Tip
When a patient scores positive on the DAST-10, resist the temptation to immediately focus on which drugs they are using and how much. Instead, first explore the patient's own perception of their drug use and their readiness for change. Using motivational interviewing techniques, ask open-ended questions like 'What role do drugs play in your life?' and 'What concerns, if any, do you have about your drug use?' This patient-centered approach builds therapeutic alliance and produces more honest disclosure than direct interrogation about specific substances and quantities.
Did you know?
Dr. Harvey Skinner developed the original 28-item DAST in 1982 by adapting the Michigan Alcoholism Screening Test (MAST) to drug use. He essentially took the MAST, replaced every mention of 'alcohol' with 'drugs,' and then refined and validated the resulting instrument. This elegant approach leveraged decades of alcohol screening research and produced a drug screening tool that has now been used in over 3,000 published studies worldwide. The 10-item version has become so dominant that many clinicians are not even aware that longer versions exist.
Get Weekly Math Tips
Join 12,000+ subscribers who get calculator tips every week.